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Fumarate hydratase (FH) is a tumor suppressor, but how it acts is unclear. Two reports in this issue of
Cancer Cell reveal that FH deficiency leads to succination of Keap1, stabilization of Nrf2, and induction of
stress-response genes including HMOX1, which is important for the survival of FH-deficient cells.The fumarate hydratase gene (FH) en-
codes a TCA cycle enzyme and functions
as a tumor suppressor gene. Heterozy-
gous germline FH mutations result in
hereditary leiomyomatosis and renal cell
cancer (HLRCC), a syndrome character-
ized by smooth muscle tumors and papil-
lary renal cell carcinoma type 2 (pRCC-2)
(Tomlinson et al., 2002). In tumors, the
wild-type FH allele is lost, and FH function
is abrogated. pRCC-2 tumors in patients
with HLRCC tend to metastasize early,
and currently, there is no therapy.
How FH suppresses tumor formation is
unknown. FH loss causes fumarate accu-
mulation in tumor cells, and fumarate is
a competitive inhibitor of 2-oxoglutarate-
dependent prolyl hydroxylase domain-
containing proteins (PHD) that hydrox-
ylate HIFa. When hydroxylated, HIFa is
recognized by the pVHL E3 ubiquitin
ligase complex and is degraded. BecauseVHL is frequently mutated in renal cancer
leading to HIF stabilization, a model
whereby HIF is upregulated in pRCC-2
as a consequence of PHD inhibition by
fumarate is attractive. However, the im-
portance of PHD inhibition and HIF stabi-
lization in the development of FH-defi-
cient tumors remains unknown.
Keap1 is the substrate recognition sub-
unit of a Cul3-based E3 ubiquitin ligase
complex that regulates Nrf2, a pivotal
transcription factor in the antioxidant re-
sponse. Keap1 proteins dimerize through
anN-terminal BTB domain, which through
an intervening region (IVR) is linked to a
C-terminal DC domain that contains
a b-propeller made up largely of kelch
repeats (Figure 1A). Two b-propellers in a
Keap1 dimer interact with an Nrf2 mono-
mer. Nrf2 contains two different Keap1-
interacting motifs. Binding through both
motifs is required for Nrf2 degradation,which led to a ‘‘hinge and latch’’ model
(Hayes et al., 2010; Taguchi et al., 2011).
Under normal conditions, Keap1 pro-
motes Nrf2 ubiquitylation and proteoso-
mal-mediated degradation. However, in
the presence of electrophiles or reactive
oxygen species, Keap1 is modified at
several reactive Cys residues, resulting in
Nrf2 stabilization and the activation of a
protective gene expression program that
includes HMOX1, an archetypal stress
response gene (Hayes et al., 2010).
In this issue of Cancer Cell, Ooi et al.
(2011) and Adam et al. (2011) show that
FH loss results in Keap1 inactivation and
Nrf2-dependent activation of antioxidant
pathways. Through gene expression anal-
yses, both groups discovered that FH
deficiency was associated with increased
expression of antioxidant genes, and this
was accompanied by the accumulation
of Nrf2. Reconstitution of FH-deficient
AB
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Figure 1. A Proposed Update of the Keap1 ‘‘Hinge and Latch’’ Model of Nrf2 Degradation
(A) Cartoon model of Keap1 dimer bound to Nrf2. In the active state (left), two DC domains are oriented to
simultaneously bind Nrf2 high-affinity (**) and low-affinity (*) sites. Right panel illustrates the inactive state
induced by Cys151 and Cys288 modification. According to our model, Cys151 modification causes rotation
to a linear conformation and the release of Cul3. We propose that Cys288 modification misorients the DC
domain with respect to the IVR.
(B) Potential structural context of proposed ‘‘hinge.’’ Two Keap1-related structures with BTB and IVR
domains have been reported: KLHL11 (PDB accession code: 3i3n) and Gigaxonin (PDB accession code:
3hve). These two proteins exhibit the same domain organization as Keap1: BTB and IVR followed by
a domainmade up of kelch repeats. KLHL11 (faded tones) differs fromGigaxonin (deeper colors) by a rota-
tion of the IVR domain (cyan) with respect to the BTB domain (blue) (the two states are marked by arrows).
We propose that Keap1 exists in two conformations corresponding to these two structures and that rota-
tion from one to the other (‘‘hinge’’) is brought about by Cys151 modification. The ‘‘hinge’’ motion causes
a change in the putative Cul3-binding site (green dots), which we determined by superimposing a Cul1-
bound BTB domain (PDB accession code: 1ldk). Thus, the hinge motion may be linked to Cul3 release.
(C) Potential structural context of proposed ‘‘latch.’’ Left view is a surface representation of a hypothetical
degradation competent, V-shaped Keap1 dimer interacting with both Nrf2-binding motifs. Right view is
a surface representation of a hypothetical degradation incompetent, linear Keap1 dimer that cannot
bindbothNrf2motifs simultaneously. Keap1DCdomains (fromPDBaccessioncode: 2flu, red)wereplaced
relative to the IVR domains (cyan) using the following considerations: (1) EM density pictures suggesting
a general positioning of the DC domain with respect to the IVR; (2) identification of a conserved DC surface
patch, which includedCys288, that was placed near the IVR; and (3)maintaining the ‘‘latch’’ distance of Nrf2
DC-bindingmotifs located on either side of a helix (wheat). The orientation of theDCdomain toward a posi-
tion unfavorable for binding theNrf2 low-affinity site (right)maybe triggered by eithermodification ofCys151
resulting in a rotation from a V-shape (left) to a linear dimer (right), as described in (B), or modification of
Cys288 resulting in a misorientation of the DC domain with respect to the IVR.
Cancer Cell
Previewscells with wild-type FH or an extramito-
chondrial FH decreased fumarate levels
and restored Nrf2 regulation (Adam
et al., 2011; Ooi et al., 2011). Complemen-
tarily, a membrane-permeable fumarate
ester was sufficient to induce Nrf2 (Ooiet al., 2011). Thus, Nrf2 regulation ap-
peared to be linked to fumarate levels.
Pollard and colleagues (Bardella et al.,
2011) had previously shown that in
FH-deficient tumor cells, fumarate spon-
taneously reacts with Cys thiol groups inCancer Cell 20proteins to form S-(2-succinyl) Cys (2SC)
adducts, and both groups asked whether
Keap1 was succinated. Using an anti-
2SC antibody, ectopically expressed
Keap1 was found to be succinated in
FH-deficient, but not wild-type cells
(Adam et al., 2011). MS/MS analyses re-
vealed succination at several Cys previ-
ously shown to be electrophile targets,
including Cys151 and Cys288 (Adam
et al., 2011; Ooi et al., 2011).
How Cys151 and Cys288 modification
affects Keap1 remains an unresolved
question (Hayes et al., 2010). Notably,
whereas Ser substitution of Cys288 abol-
ishes Keap1 function and stabilizes Nrf2,
Ser substitution of Cys151 does not affect
Nrf2 degradation. However, substitution
of Cys151 by amino acids with progres-
sively bulkier side chains causes progres-
sive loss of Keap1 function, suggesting
that the effect at this site is steric (Hayes
et al., 2010).
Placing Cys151 and Cys288 residues in
a structural context should help unravel
their role. Our analysis of two Keap1-
related structures (Zhuang et al. [2009];
see also Figure 1 legend) suggests that
the IVR rotates with respect to the BTB
domain, giving rise to either a linear or a
V-shape dimer (Figure 1A). The rotation
may affect the interaction with Cul3 be-
cause it causes a change in the conforma-
tion of a Cul3-binding ‘‘3-box’’ within the
IVR (Zhuang et al., 2009) (see also
Figure 1B). Interestingly, Cys151 is at the
bending point, and we propose that suc-
cination induces the linear state and
releases Cul3, resulting in Nrf2 stabiliza-
tion (Figure 1C). Although the structural
context of Cys288 is less clear, the IVR,
where Cys288 is located, closely associ-
ated with the DC domain in a low-resolu-
tion electron microscopy model of
Keap1 (Ogura et al., 2010). Interestingly,
Cys288 was found to form part of a con-
served surface patch that we postulate
interacts with the DC domain and that
placed Cys288 in close proximity with
Cys613. We propose that these two Cys
stabilize the interaction between the IVR
and DC domains either through a disulfide
bond or metal coordination (together with
Glu289 and His246) and that modification of
Cys288 (and Cys613) abrogates this inter-
action (Figure 1A).
Ooi et al. (2011) report that Nrf2 target
genes are induced also in sporadic
pRCC-2. However, in contrast to familial, October 18, 2011 ª2011 Elsevier Inc. 419
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PreviewspRCC-2, mutations in FH have not been
detected in sporadic pRCC-2, and spo-
radic pRCC-2 tumors do not accumulate
succinated proteins (Bardella et al.,
2011). Thus, how antioxidant genes are
upregulated in sporadic pRCC-2 remains
unclear.
The contribution of antioxidant genes
to renal tumorigenesis in patients with
HLRCC requires further exploration. How-
ever, there is precedent implicating Keap1
and Nrf2 in tumor development. Somati-
cally acquired loss-of-function KEAP1
mutations have been found in tumors (Ta-
guchi et al., 2011). Nrf2 is also stabilized
in tumors by mutation in either of the two
motifs involved in Keap1 binding that are
necessary for its degradation (Taguchi
et al., 2011). Consistent with the notion
that these two proteins function in
concert, mutations in KEAP1 and NRF2
tend not to be observed together in the
same tumor (Taguchi et al., 2011).
Understanding the biology of HLRCC-
associated pRCC-2 will hopefully lead to
new therapies. Because FH is lost in
tumor cells, and this truncates the TCA
cycle, these tumors may be exquisitely
dependent on glycolysis for energy
generation. As determined by 2-deoxy-
2-(18F)fluoro-D-glucose (FDG) positron
emission tomography (PET), FH-deficient420 Cancer Cell 20, October 18, 2011 ª2011tumors take up large amounts of glucose
(Yamasaki et al., 2011). Although exploit-
ing this dependency may be challenging
(Yamasaki et al., 2011), this may offer an
opportunity for therapeutic intervention.
Recently, HMOX1, which is required
for heme synthesis and is upregulated in
FH-deficient tumors, was proposed as a
therapeutic target (Frezza et al., 2011).
FH-deficient cells maintain segmental
TCA cycle function and NADH generation
by using glutamine and disposing of
excess carbon through the synthesis of
heme and its excretion from the cell as
bilirubin (Frezza et al., 2011). Interestingly,
inhibition of HMOX1 is synthetically lethal
with FH deficiency. However, the selec-
tivity of this approach in patients remains
to be determined, particularly because
HLRCC patients are heterozygous for
FH, and mutant FH may be incorporated
into FH homotetramers, markedly re-
ducing FH activity in non-neoplastic cells.
Nonetheless, this concept deserves to be
studied further in primary xenografts and,
subsequently, in patients.
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Reports of whole-exome sequencing in myelodysplastic syndrome (MDS) patients by Yoshida et al. and
Papaemmanuil et al. suggest spliceosome mutations have clinical relevance. Identifying the impact of these
mutations on MDS pathogenesis holds promise for therapeutic modulation of mRNA splicing.The myelodysplastic syndromes (MDSs)
are a heterogeneous group of myeloid
malignancies characterized by clonal he-
matopoiesis, impaired differentiation, pe-
ripheral blood cytopenias, and increasedrisk of progression to acute myeloid leu-
kemia. Although recent studies have iden-
tified recurrent somatic mutations in most
patients with MDS, approximately 20% of
patients with MDS had no known somaticgenetic or cytogenetic abnormalities in
the largest studies to date. Two recent
studies report the results of whole-exome
sequencing in patients with MDS (Pa-
paemmanuil et al., 2011; Yoshida et al.,
